LogicBio Therapeutics Inc (OQ:LOGC)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 99 Erie St
CAMBRIDGE MA 02139-4559
Tel: N/A
Website: https://www.logicbio.com
IR: See website
Key People
Frederic Chereau
President, Chief Executive Officer
Matthias B. Jaffe
Chief Financial Officer
Dean Falb Falb
Chief Scientific Officer
Tom Wilton
Chief Business Officer
Business Overview
LogicBio Therapeutics, Inc. is a genome editing company. The Company is focused on developing medicines to treat rare diseases in patients with unmet medical need. Its GeneRide technology platform is designed to integrate corrective genes into a patient's genome to provide a stable therapeutic effect. It focuses on targeting rare liver disorders in pediatric patients. Its discovery, research and development programs include various candidate, including LB-001, LB-101, LB 201 and LB-301. It is developing its lead product candidate, LB-001, for the treatment of Methylmalonic Acidemia. LB-001 consists of a deoxyribonucleic acid construct including a gene encoding the human methylmalonyl CoA mutase (MUT) enzyme encapsulated in an AAV capsid. It is developing LB-101 for the treatment of Hemophilia B. LB-201 is being developed for the treatment of alpha-1-antitrypsin deficiency (A1ATD). The Company is developing LB-301 for the treatment of Crigler-Najjar syndrome animal disease models.
Financial Overview
For the nine months ended 30 September 2019, LogicBio Therapeutics Inc revenues was not reported. Net loss increased from $10.6M to $28.7M. Higher net loss reflects Research and develop increase from $6M to $21.7M (expense), General and administrative - Ba increase of 61% to $6.6M (expense), Stock-based Compensation in R&D increase from $147K to $553K (expense).
Employees: 23 as of Dec 31, 2018
Reporting Currency: U.S. Dollars
Enterprise value: $146.96M as of Sep 30, 2019
Annual revenue (TTM): $0.00M as of Sep 30, 2019
EBITDA (TTM): -$36.76M as of Sep 30, 2019
Net annual income (TTM): -$35.72M as of Sep 30, 2019
Free cash flow (TTM): -$33.02M as of Sep 30, 2019
Net Debt Last Fiscal Year: N/A
Shares outstanding: 22,765,930 as of Sep 30, 2019
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization